iGenetic Diagnostics and the Indian diagnostic sector


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴
Do you know the diagnostic industry of our country is worth $9 billion? One such leading Indian pathology chain is Mumbai-based iGenetic Diagnostics.

Do you know the diagnostic industry of our country is worth $9 billion? It had a growth rate of a mere 6% in 2018 to having 20-25% in 2021. Within this, the high-end services constitute 9%.

In 2015 the Government of India under the aegis of National Health Mission launched the Free Diagnostic Service Initiative. This pushed all states and UTs to provide free cost essential diagnostics. In 2019, India became the first country where the government took the initiative to compile the National Essential Diagnostic List which mandates certain tests be available at the remotest of the village. The Union Budget 2020, kept ₹759 crores aside to make sure all Indian states can administer free diagnostic services. 

One such leading Indian pathology chain is Mumbai-based iGenetic Diagnostics. Launched in 2013 by Arunima Patel, Homer Paneri and Siddharth Patodia, it provides 1400 + general and advanced molecular diagnostics, genetic sequencing and cytogenetics tests.

The three founders were part of the healthcare sector and wanted to build a venture that used molecular biology in testing to create better and quicker lab results. For this, they build a dedicated team of scientists and researchers and launched their operations in 2015. Initially, they started with a seed fund worth ₹10 crores that was gained by numerous sources including the founders adding their own money. Later in 2015, they received ₹9 crores from an angel investor.

 Their biggest breakthrough was when the UK government’s financial institution, CDC Group Plc and Manipal Education and Medical Group (MEMG) invested ₹130 crores. With the funds, they plan to expand their operations from the current 4 locations in India. As of 2017, they had their headquarters in Mumbai and five satellite laboratories spread in Mumbai, Nagpur, Hyderabad and Ahmedabad. 

In 2018, iGenetic Diagnostics made a collaboration with Lucence Diagnostics. The latter is a Singapore-based genomic medicine company. The deal between these two allows Lucence Diagnostics’s liquid biopsy test to be available in India. Diagnostics is not only a great addition to preventive healthcare but also to the Indian economy. They save the lives of many by pre-screening major illnesses. This increases the overall productivity of our country’s citizens. Do you agree?

Tags : #iGeneticDiagnostics #GoI #NationalHealthMission #ArunimaPatel #HomerPaneri #SiddharthPatodia #LucenceDiagnostics #CDCGroupPlc #ManipalEducationandMedicalGroup #funding #corporatealert #startupfunding #medispeak #smitakumar #medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

AI-Enabled Endoscopy: Can It Detect More Than the Human Eye?November 20, 2026
AI-Enabled Endoscopy: Can It Detect More Than the Human Eye?November 20, 2026
Hospital-at-Home in India: Can Technology Deliver Safe Care?November 20, 2026
Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026